Prime Medicine’s (PRME) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Prime Medicine (NASDAQ:PRME) in a research note issued to investors on Monday,Benzinga reports. They currently have a $8.00 target price on the stock. HC Wainwright also issued estimates for Prime Medicine’s Q3 2026 earnings at ($0.28) EPS, Q4 2026 earnings at ($0.32) EPS, FY2026 earnings at ($1.11) EPS, Q2 2027 earnings at ($0.23) EPS, FY2027 earnings at ($0.91) EPS, FY2028 earnings at ($0.92) EPS, FY2029 earnings at ($0.96) EPS and FY2030 earnings at ($0.81) EPS.

Other equities research analysts have also recently issued reports about the stock. Wall Street Zen upgraded shares of Prime Medicine from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 8th. The Goldman Sachs Group set a $6.00 price objective on Prime Medicine in a research note on Monday, June 22nd. Weiss Ratings restated a “sell (e+)” rating on shares of Prime Medicine in a report on Wednesday, June 3rd. TD Cowen reaffirmed a “buy” rating on shares of Prime Medicine in a research report on Wednesday, July 8th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Prime Medicine in a report on Monday, June 22nd. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Prime Medicine has an average rating of “Moderate Buy” and a consensus price target of $7.53.

Prime Medicine Stock Performance

Shares of NASDAQ PRME opened at $3.20 on Monday. Prime Medicine has a 1 year low of $2.67 and a 1 year high of $6.94. The firm has a market cap of $580.41 million, a P/E ratio of -3.02 and a beta of 2.31. The stock has a fifty day moving average price of $3.27 and a two-hundred day moving average price of $3.46.

Prime Medicine (NASDAQ:PRME) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.24) earnings per share for the quarter, meeting the consensus estimate of ($0.24). Prime Medicine had a negative return on equity of 156.84% and a negative net margin of 4,613.11%.The business had revenue of $1.15 million during the quarter, compared to analyst estimates of $4.40 million. On average, research analysts predict that Prime Medicine will post -0.97 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Prime Medicine

Large investors have recently bought and sold shares of the business. Creative Planning bought a new position in Prime Medicine during the second quarter valued at about $25,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Prime Medicine during the 4th quarter valued at about $31,000. Royal Bank of Canada increased its holdings in shares of Prime Medicine by 89.3% during the 1st quarter. Royal Bank of Canada now owns 9,254 shares of the company’s stock valued at $32,000 after acquiring an additional 4,365 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new position in shares of Prime Medicine in the 4th quarter valued at approximately $33,000. Finally, Glen Eagle Advisors LLC acquired a new stake in Prime Medicine in the 4th quarter worth approximately $35,000. 70.37% of the stock is currently owned by institutional investors.

Key Prime Medicine News

Here are the key news stories impacting Prime Medicine this week:

• Positive Sentiment: Prime Medicine announced progress toward a first-in-human clinical study of PM577 for Wilson disease. Advancing the company’s prime-editing platform into human testing may improve investor confidence, although the program remains early stage. Prime Medicine Advances First-in-Human Prime Editing Trial in Wilson Disease
• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $8 price target for Prime Medicine, implying substantial upside from recent trading levels. The firm also raised its FY2026 EPS forecast to a loss of $1.11 from a loss of $1.17, increased its Q3 2026 forecast to a loss of $0.28 from $0.29, and improved its FY2028 estimate to a loss of $0.92 from $1.01. HC Wainwright Reaffirms Buy Rating for Prime Medicine
• Neutral Sentiment: Reported short interest was listed at zero shares, with a zero-day days-to-cover ratio. Because the data shows no measurable short position, it offers little indication of meaningful short-covering demand or additional selling pressure.
• Negative Sentiment: HC Wainwright made several modest downward revisions: Q4 2026 EPS to a loss of $0.32 from $0.31, FY2027 to a loss of $0.91 from $0.90, FY2029 to a loss of $0.96 from $0.85, and FY2030 to a loss of $0.81 from $0.67. The revisions reinforce expectations that Prime Medicine will remain unprofitable for years, even though the analyst continues to rate the shares Buy.

Prime Medicine Company Profile

We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology. Genetic mutations implicated in disease are diverse and can range from errors of a single base, known as point mutations, to errors that extend beyond a single base, such as insertions, deletions, duplications, or combinations thereof.